What are the appropriate dosing, contraindications, and precautions for prescribing Doxepin in an adult with depression or anxiety?

Doxepin Prescribing Guide for Depression and Anxiety in Adults

For adults with depression or anxiety, start doxepin at 75 mg daily for mild-to-moderate illness, with a therapeutic range of 75-150 mg/day; elderly or frail patients should begin at 25 mg daily and titrate cautiously. 1

Dosing Algorithm

Initial Dosing by Severity and Patient Characteristics

Mild-to-Moderate Depression/Anxiety:

• Start: 75 mg daily (can be given as single bedtime dose or divided)
• Titrate: Increase or decrease at appropriate intervals based on response
• Target range: 75-150 mg/day
• Maximum: 150 mg/day if using once-daily bedtime dosing 1

Severe Depression:

• Start: 75 mg daily
• Titrate: Gradually increase to 300 mg/day if necessary
• Maximum: 300 mg/day (rarely provides additional benefit beyond this dose) 1

Very Mild Symptoms/Emotional Symptoms with Organic Disease:

• Start: 25-50 mg/day
• Many patients controlled at these lower doses 1

Elderly or Frail Patients:

• Start: 25 mg daily at bedtime
• Titrate: Increase by 25 mg every 3-7 days as tolerated
• Use cautious, slow titration due to increased risk of confusion and oversedation
• Maximum: Generally keep below 150 mg/day 1

Titration Principles

The evidence shows marked interpatient variability (>20-fold) in steady-state plasma concentrations at fixed doses 2. This means you cannot predict individual response from population averages. Start low in elderly patients, those with cardiovascular disease, or hepatic impairment, and titrate based on clinical response and tolerability.

Critical Contraindications

Absolute Contraindications:

• Concurrent MAOI use or within 14 days of MAOI discontinuation (risk of serotonin syndrome)
• Acute recovery phase following myocardial infarction
• Untreated narrow-angle glaucoma (pupillary dilation can trigger angle-closure attack) 1

Relative Contraindications (Use with Extreme Caution):

• Urinary retention
• Severe hepatic or renal impairment
• Cardiac conduction abnormalities or arrhythmias
• History of seizures
• Bipolar disorder risk (screen thoroughly before initiating—may precipitate manic episode) 1

Essential Precautions and Monitoring

Black Box Warning: Suicidality Risk

Increased suicidal thinking and behavior in patients <25 years old, especially during initial treatment and dose changes. Monitor closely for:

• Clinical worsening
• Suicidality
• Unusual behavior changes
• Anxiety, agitation, panic attacks
• Insomnia, irritability, hostility
• Aggressiveness, impulsivity, akathisia
• Hypomania or mania 1

This risk is highest in the first few months of treatment and with any dose adjustments. Write prescriptions for the smallest quantity consistent with good management to reduce overdose risk 1.

Cardiovascular Precautions

Obtain baseline ECG in patients >40 years old before initiating therapy. Doxepin can cause:

• QRS widening (QRS ≥0.10 seconds indicates severe toxicity)
• QT prolongation
• Cardiac arrhythmias
• Orthostatic hypotension (though less common than with other tricyclics)
• Tachycardia 1

Use with extreme caution in patients with ischemic heart disease or ventricular conduction abnormalities. While doxepin causes fewer cardiovascular side effects at therapeutic doses compared to other tricyclics 3, it retains significant cardiotoxicity in overdose 3.

Anticholinergic Effects

Common and dose-related:

• Dry mouth (most common)
• Blurred vision
• Constipation
• Urinary retention

If severe or persistent, reduce dosage 1. These effects are particularly problematic in elderly patients who may already have prostatic hypertrophy or decreased bowel motility.

CNS Effects

Drowsiness is the most common side effect and typically improves with continued therapy 1. This sedative property makes doxepin particularly useful for depressed patients with sleep disturbances 3. However, warn patients about:

• Impaired alertness (avoid driving/operating machinery initially)
• Confusion and disorientation (especially elderly)
• Risk of falls (particularly in elderly or frail patients)

Less common CNS effects include hallucinations, seizures, extrapyramidal symptoms, and tardive dyskinesia 1.

Drug Interactions

Critical interactions requiring dose adjustment or avoidance:

1. CYP450 Enzyme Interactions: Doxepin clearance varies significantly with concurrent medications 2

   • Enzyme inducers (e.g., carbamazepine, phenytoin, smoking): Increase doxepin clearance >3-fold, may require higher doses
   • Enzyme inhibitors (e.g., SSRIs, cimetidine): Decrease clearance >3-fold, may require lower doses 2

2. Serotonergic Drugs: Avoid combining with MAOIs (absolute contraindication). Use caution with SSRIs, SNRIs, triptans, tramadol—risk of serotonin syndrome

3. QT-Prolonging Drugs: Additive risk of arrhythmias

4. CNS Depressants: Additive sedation with alcohol, benzodiazepines, opioids

Hepatic and Renal Impairment

Reduce doses in patients with hepatic impairment. While the extent of renal excretion is not fully determined, use caution in renal impairment and start with lower doses 1.

Special Populations

Elderly Patients

Start at 25 mg daily and titrate slowly. Elderly patients are at higher risk for:

• Confusion and oversedation
• Falls
• Anticholinergic effects
• Cardiovascular effects
• Decreased hepatic and renal function 1

The once-daily bedtime dosing regimen should be adjusted carefully based on individual response. Maximum recommended dose for once-daily dosing is 150 mg/day 1.

Pregnancy and Lactation

Safety not established in pregnancy. Apnea and drowsiness reported in nursing infants whose mothers took doxepin—use caution or consider alternative 1.

Children

Not recommended for children <12 years old—safety and efficacy not established 1.

Common Pitfalls to Avoid

1. Underdosing: Real-world data shows mean maximum dosages of only 83 mg/day, with only 6.1% of patients receiving ≥150 mg/day 4. While physicians adaptively adjust doses based on severity and tolerability, many patients may not reach therapeutic doses. Don't stop at 75 mg if response is inadequate—titrate to 150 mg/day for most patients.

2. Inadequate Trial Duration: Anti-anxiety effects appear before antidepressant effects. Optimal antidepressant effect may not be evident for 2-3 weeks 1. Don't switch medications prematurely.

3. Abrupt Discontinuation: Withdrawal symptoms can occur with abrupt cessation after prolonged use. Taper gradually to avoid discontinuation syndrome (though less problematic than with shorter-acting SSRIs) 1.

4. Missing Bipolar Disorder: Screen thoroughly for bipolar disorder before initiating. Treating bipolar depression with an antidepressant alone may precipitate manic/mixed episodes 1.

5. Ignoring Pharmacokinetic Variability: At doses approaching 300 mg/day, some patients approach maximum metabolic capacity (Vmax), leading to disproportionate increases in plasma concentrations with dose increments 2. Monitor closely for toxicity when using higher doses.

6. Overdose Risk: Doxepin is highly toxic in overdose, causing cardiac arrhythmias, severe hypotension, convulsions, and CNS depression. Deaths have been reported 1. Prescribe limited quantities, especially in suicidal patients.

Advantages of Doxepin

Compared to other tricyclics, doxepin offers:

• Fewer cardiovascular side effects at therapeutic doses (though similar cardiotoxicity in overdose) 3
• Better tolerability than imipramine or amitriptyline at equivalent doses 3
• Marked sedative properties useful for depression with insomnia or anxiety 3
• Safety in long-term use (5-15 years) with minimal adverse drug interactions 5
• Efficacy in elderly and cardiovascular disease patients when dosed appropriately 5

When anxiety accompanies significant depression, doxepin is more effective than benzodiazepines alone 3.